RE: BerGenBio Nyheter | Finansavisen Forum
finansavisen.no › forum › threadJan 10, 2021 · Flink forsker som også har trua på BerGenBio…. BERGENBIO ANNOUNCES POSTER PRESENTATION AT SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) ANNUAL MEETING 2021. Bergen, Norway, 01 October 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need ...
BerGenBio - Investors
www.bergenbio.com › investorsMar 17, 2022 · BerGenBio (OSE:BGBIO) is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases, including immune evasive, drug resistant and metastatic cancers.
RE: BerGenBio Nyheter | Finansavisen Forum
https://finansavisen.no/forum/thread/140711/view01.10.2021 · Bergen, Norway, 01 October 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that it will deliver an e-poster presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting, taking place online from 10-14 …
Ticker: BGBIO | Finansavisen Forum
https://finansavisen.no/forum/ticker/BGBIO12.09.2020 · Forum Ticker Siste Innlegg Svar Lest Av; Farma: BGBIO 13:20: BerGenBio Nyheter 205167 BioBull 22.03.2022; Forum Ticker Siste Innlegg Svar Lest Av; Farma: BGBIO 12:09: BGBIO Aksjonæroversikt 38024 BioBull 11.02.2022; Forum Ticker Siste Innlegg Svar Lest Av; Farma: BGBIO 09:19: INNSIDER OG CEO kjøper seg opp i BERGENBIO 7013 klaesp 02.02.2022; Forum
BerGenBio - Developing first-in-class AXL inhibitors for ...
https://www.bergenbio.com17.03.2022 · BerGenBio and Oslo University Hospital Announce the AXL Inhibitor Bemcentinib will be Studied in the EU Funded EU-SolidAct trial in Hospitalised COVID-19 Patients Bergen/Oslo, Norway 27 January 2022 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs and Oslo …
News - BerGenBio
www.bergenbio.com › media-centre › newsMar 17, 2022 · BerGenBio and Oslo University Hospital Announce the AXL Inhibitor Bemcentinib will be Studied in the EU Funded EU-SolidAct trial in Hospitalised COVID-19 Patients. January 27, 2022. Bergen/Oslo, Norway 27 January 2022 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…. Read More.
Ticker: BGBIO | Finansavisen Forum
finansavisen.no › forum › tickerForum Ticker Siste Innlegg Svar Lest Av; Farma: BGBIO 09:19: INNSIDER OG CEO kjøper seg opp i BERGENBIO 7013 klaesp 02.02.2022; Forum Ticker Siste Innlegg Svar Lest Av; Farma: BGBIO 13:31: WhatsUp with BerGenBio? 26128 Move Along 31.01.2022; Forum Ticker Siste Innlegg Svar Lest Av; Farma: BGBIO 10:53: Covid og BerGenBio 2800 A-Spekulant1 12.01 ...